WO2009069668A1 - Agent for increasing the expression of malignant melanoma antigen, and use thereof - Google Patents

Agent for increasing the expression of malignant melanoma antigen, and use thereof Download PDF

Info

Publication number
WO2009069668A1
WO2009069668A1 PCT/JP2008/071469 JP2008071469W WO2009069668A1 WO 2009069668 A1 WO2009069668 A1 WO 2009069668A1 JP 2008071469 W JP2008071469 W JP 2008071469W WO 2009069668 A1 WO2009069668 A1 WO 2009069668A1
Authority
WO
WIPO (PCT)
Prior art keywords
expression
agent
increasing
malignant melanoma
melanoma antigen
Prior art date
Application number
PCT/JP2008/071469
Other languages
French (fr)
Japanese (ja)
Inventor
Michihiro Kono
Yasushi Tomita
Original Assignee
National University Corporation Nagoya University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Nagoya University filed Critical National University Corporation Nagoya University
Priority to JP2009543831A priority Critical patent/JP5397692B2/en
Publication of WO2009069668A1 publication Critical patent/WO2009069668A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Abstract

Disclosed is a means which is effective for the treatment of melanoma. Specifically disclosed is an agent for increasing the expression of a malignant melanoma antigen, which comprises a compound selected from the group consisting of methotrexate, paclitaxel, daunorubicin hydrochloride (daunorubicin, HCl), doxorubicin hydrochloride (doxorubicin, HCl), actinomycin D, camptothecin, etoposide, cytochalasin D, 3-ATA (3-amino-9-thio(10H)-acridone), aphidicolin, bisindolylmaleimide I, an arabino nucleoside (cytosine arabinoside), curcumin, 2',3'-dideoxythymidine triphosphate (2',3'-dideoxythymidine 5'-triphosphate), a thymidine dimer (dipyrimidine dithymidylic acid), pyridoxal phosphate (pyridoxal 5'-phosphate hydrate), epigallocatechin gallate ((-)-epigallocatechin gallate), vidarabine, resveratrol and lithocholic acid.
PCT/JP2008/071469 2007-11-28 2008-11-26 Agent for increasing the expression of malignant melanoma antigen, and use thereof WO2009069668A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009543831A JP5397692B2 (en) 2007-11-28 2008-11-26 Malignant melanoma antigen expression increasing agent and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-307905 2007-11-28
JP2007307905 2007-11-28
JP2008124220 2008-05-12
JP2008-124220 2008-05-12

Publications (1)

Publication Number Publication Date
WO2009069668A1 true WO2009069668A1 (en) 2009-06-04

Family

ID=40678561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/071469 WO2009069668A1 (en) 2007-11-28 2008-11-26 Agent for increasing the expression of malignant melanoma antigen, and use thereof

Country Status (2)

Country Link
JP (1) JP5397692B2 (en)
WO (1) WO2009069668A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121097A (en) * 2014-12-25 2016-07-07 有限会社イムノ Drugs for inducing immune response
WO2018038425A1 (en) * 2016-08-24 2018-03-01 (주)아모레퍼시픽 Skin-whitening composition containing cytochalasin d
WO2019228108A1 (en) * 2018-05-28 2019-12-05 福建师范大学 Reagent composition used for increasing cell transfection efficiency
US11111493B2 (en) 2018-03-15 2021-09-07 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289524A (en) * 1985-02-01 1987-12-16 スロ−ン−ケツタリング　インステイテユ−ト　フオ−　キヤンサ−　リサ−チ Remedy for human nerve ectodermal malignant tumor and epithelial cancer
JPH03505744A (en) * 1989-04-28 1991-12-12 シラキューズ　ユニバーシティ Cytochalasin compositions and treatments
JPH04264083A (en) * 1991-02-15 1992-09-18 Nippon Mektron Ltd Aphidicolan derivative and its production
JPH08268917A (en) * 1995-03-31 1996-10-15 D D S Kenkyusho:Kk Antitumor agent having high transition to cancer tissue
JP2003515535A (en) * 1999-11-16 2003-05-07 ザ ゼネラル ホスピタル コーポレーション Compositions and methods for modulating tumor-associated antigen expression
WO2004019886A2 (en) * 2002-08-29 2004-03-11 Cytocure Llc Methods for up-regulating antigen expression in tumors
WO2004087941A1 (en) * 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
JP2006523206A (en) * 2003-03-27 2006-10-12 メディキュア インコーポレーテッド Regulation of cell death
WO2006122431A1 (en) * 2005-05-19 2006-11-23 Prometic Biosciences Inc. Triazine compounds and compositions thereof for the treatment of cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155239A (en) * 1985-12-27 1987-07-10 Rikagaku Kenkyusho Aphidicolin derivative, synthesis thereof and carcinostatic agent

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289524A (en) * 1985-02-01 1987-12-16 スロ−ン−ケツタリング　インステイテユ−ト　フオ−　キヤンサ−　リサ−チ Remedy for human nerve ectodermal malignant tumor and epithelial cancer
JPH03505744A (en) * 1989-04-28 1991-12-12 シラキューズ　ユニバーシティ Cytochalasin compositions and treatments
JPH04264083A (en) * 1991-02-15 1992-09-18 Nippon Mektron Ltd Aphidicolan derivative and its production
JPH08268917A (en) * 1995-03-31 1996-10-15 D D S Kenkyusho:Kk Antitumor agent having high transition to cancer tissue
JP2003515535A (en) * 1999-11-16 2003-05-07 ザ ゼネラル ホスピタル コーポレーション Compositions and methods for modulating tumor-associated antigen expression
WO2004087941A1 (en) * 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
WO2004019886A2 (en) * 2002-08-29 2004-03-11 Cytocure Llc Methods for up-regulating antigen expression in tumors
JP2006523206A (en) * 2003-03-27 2006-10-12 メディキュア インコーポレーテッド Regulation of cell death
WO2006122431A1 (en) * 2005-05-19 2006-11-23 Prometic Biosciences Inc. Triazine compounds and compositions thereof for the treatment of cancers

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Annals of the New York Academy of Sciences", vol. 446, 1985, article GHOSE, T. ET AL.: "Antibodies as carriers of cancer chemotherapeutic agents", pages: 213 - 227 *
AOYAGI, Y. ET AL.: "In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 90, no. 5, 1999, pages 578 - 587 *
AQUINO, A. ET AL.: "Drug-induced increase of carcinoembryonic antigen expression in cancer cells", PHARMACOLOGICAL RESEARCH, vol. 49, no. 5, 2004, pages 383 - 396 *
ARNOULD, R. ET AL.: "Compared cytotoxicity effects of five anticancer drugs on human (HBL) and mouse (B16) melanoma cells in vitro", ANTICANCER RESEARCH, vol. 10, no. 3, 1990, pages 789 - 793 *
BAJETTA, E. ET AL.: "Metastatic melanoma: chemotherapy", SEMINARS IN ONCOLOGY, vol. 29, no. 5, 2002, pages 427 - 445 *
BUSH, J.A. ET AL.: "Curcumin induces apoptosis in human melanoma cells through a Fas receptor/ caspase-8 pathway independent of p53", EXPERIMENTAL CELL RESEARCH, vol. 271, no. 2, 2001, pages 305 - 314 *
CHEMICAL ABSTRACTS, vol. 142, 2005, Columbus, Ohio, US; abstract no. 142:273591R *
CHOPRA, H. ET AL.: "An in vivo study of the role of the tumor cell cytoskeleton in tumor cell- platelet-endothelial cell interactions", CANCER RESEARCH, vol. 50, no. 23, 1990, pages 7686 - 7696 *
DICCIANNI, M.B. ET AL: "3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner", JOURNAL OF EXPERIMENTAL THERAPEUTICS & ONCOLOGY, vol. VOL.4, no. NO.3, 2004, pages 223 - 237 *
HSIEH, T.C. ET AL.: "Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 334, no. 1, 2005, pages 223 - 230 *
KAZUKI NAKAMURA ET AL.: "C Kinase Sogaizai ni yoru p53 Tanpaku Rin Sanka o Kaishita Gan Saibo Kino Yokusei", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 120, no. 12, 2000, pages 1387 - 1394 *
KONO, M. ET AL.: "Aphidicolin as a possible modulating agent for melanoma antigen expression in melanoma immunotherapy", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 128, no. SUP 1, April 2008 (2008-04-01), pages S219 *
KONO, M. ET AL.: "Methotrexate as a possible modulating agent for melanoma antigen expression in melanoma immunotherapy", PIGMENT CELL & MELANOMA RESEARCH, vol. 21, no. 2, April 2008 (2008-04-01), pages 324 - 325 *
LEPAGE, G.A. ET AL.: "Responses of patients to arabinosyladenine-5'-phosphate correlated with an in vitro test", ADVANCES IN ENZYME REGULATION, vol. 17, 1978, pages 437 - 454 *
LIN, J.D. ET AL.: "Inhibition of melanoma growth and metastasis by combination with (-)- epigallocatechin-3-gallate and dacarbazine in mice", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 83, no. 4, 2001, pages 631 - 642 *
MAEDA, N. ET AL.: "Effects of DNA polymerase inhibitory and antitumor activities of lipase- hydrolyzed glycolipid fractions from spinach", THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 16, 2005, pages 121 - 128 *
MONTI, E. ET AL.: "Synergistic interactions of etoposide and interleukin-1 alpha are not due to DNA damage in human melanoma cells", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1180, no. 3, 1993, pages 231 - 235 *
NEALE, M.H. ET AL.: "Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside", BRITISH JOURNAL OF CANCER, vol. 79, no. 9-10, 1999, pages 1487 - 1493 *
PANTAZIS, P. ET AL.: "Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins", CANCER RESEARCH, vol. 52, no. 14, 1992, pages 3980 - 3987 *
SHULTZ, T.D. ET AL.: "Effect of pyridoxine and pyridoxal on the in vitro growth of human malignant melanoma", ANTICANCER RESEARCH, vol. 8, no. 6, 1988, pages 1313 - 1318 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121097A (en) * 2014-12-25 2016-07-07 有限会社イムノ Drugs for inducing immune response
WO2018038425A1 (en) * 2016-08-24 2018-03-01 (주)아모레퍼시픽 Skin-whitening composition containing cytochalasin d
KR20180022416A (en) * 2016-08-24 2018-03-06 (주)아모레퍼시픽 Composition for skin-whitening comprising cytochalasin d
KR102600091B1 (en) 2016-08-24 2023-11-09 (주)아모레퍼시픽 Composition for skin-whitening comprising cytochalasin d
US11111493B2 (en) 2018-03-15 2021-09-07 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11421228B2 (en) 2018-03-15 2022-08-23 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11608500B2 (en) 2018-03-15 2023-03-21 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019228108A1 (en) * 2018-05-28 2019-12-05 福建师范大学 Reagent composition used for increasing cell transfection efficiency

Also Published As

Publication number Publication date
JP5397692B2 (en) 2014-01-22
JPWO2009069668A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
HK1146410A1 (en) 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008039489A3 (en) 5-substituted quinazolinone derivatives as antitumor agents
WO2008013838A3 (en) Pyridizinone derivatives
WO2009026179A3 (en) Antiinfective proanthocyanidin compounds and methods of use thereof
WO2008089105A3 (en) Antiviral nucleoside analogs
MY184464A (en) Combined use of cholestanol derivative
WO2008049116A3 (en) Substituted indoles
IL192763A (en) Pyrimidine derivatives, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of cancer
DK2024352T3 (en) Glucopyranosyl substituted benzo nitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their preparation
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
IL191291A (en) Compositions comprising selenium compounds, prebiotics, phosphatides and flavonols and use thereof for preparing medicaments
WO2009073506A3 (en) Nucleoside prodrugs and uses thereof
WO2008075201A3 (en) Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2006097617A3 (en) Novel dihydropyrimidine derivatives and their use as anti-cancer agents
WO2009069668A1 (en) Agent for increasing the expression of malignant melanoma antigen, and use thereof
WO2007054100A3 (en) Lna nucleoside phosphoramidates
WO2008111096A3 (en) Novel prodrugs
CA2659376C (en) 2,4-diaminoquinazolines for spinal muscular atrophy
WO2010080414A3 (en) Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents
IL223327A0 (en) 5,6 or 7-substituted-s- (hetero) arylisoquinolinamine derivatives as antitumor agents
EP2251014A4 (en) Combined use of cholestanol derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08854988

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009543831

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08854988

Country of ref document: EP

Kind code of ref document: A1